Building Bispecifics using OmniAb’s Next-Generation Therapeutic Antibody and Alternative Scaffold Technologies
Time: 10:00 am
day: Day Two
Details:
- OmniAb’s suite of engineered animals and AI-assisted single B cell discovery workflow offer significant advantages for building bispecifics
- Our naturally optimized fully human custom immune repertoires in multiple host species and multiple modalities provide optionality for our partners and include common light chain platforms in two host species, stabilized human VHH in a chicken host and cow-inspired picobodies. Our AI-augmented single B cell workflows enable deep mining of these vast repertoires to retrieve optimum candidates for drug discovery
- We present a case study using NKp46 as an immunogen in multiple host species and assess the binding kinetics and epitope coverage to inform lead selections for building NK engagers